

# FIP representation at the 78th World Health Assembly

## Impact and success report

2025



## Colophon

Copyright 2025 International Pharmaceutical Federation (FIP)

International Pharmaceutical Federation (FIP)

Andries Bickerweg 5

2517 JP The Hague

The Netherlands

[www.fip.org](http://www.fip.org)

All rights reserved. No part of this publication may be stored in any retrieval system or transcribed by any form or means – electronic, mechanical, recording, or otherwise without citation of the source. FIP shall not be held liable for any damages incurred resulting from the use of any data and information from this report. All measures have been taken to ensure accuracy of the data and information presented in this report.

### **Authors:**

Dr Aysu Selçuk, FIP Development Goals Lead

Dr Ozge Ozer, FIP Congress Programme and Provision Manager

Dr Mariet Eksteen, FIP Head of Advocacy, Communications and Marketing

### **Editor:**

Dr Catherine Duggan, FIP Chief Executive Officer

### Recommended citation

International Pharmaceutical Federation (FIP). FIP representation at the 78th World Health Assembly: Impact and success report. The Hague: International Pharmaceutical Federation, 2025.

# Contents

<b>Acknowledgements .....</b>	<b>1</b>
<b>Foreword by FIP President .....</b>	<b>2</b>
<b>Foreword by FIP CEO .....</b>	<b>3</b>
<b>Executive summary.....</b>	<b>4</b>
<b>1 FIP Delegation at WHA78 .....</b>	<b>5</b>
1.1 FIP delegation at WHA78.....	5
1.2 FIP-WHA78 delegates' testimonials .....	7
The FIP meet and greet event .....	9
<b>2 FIP interventions at WHA78 .....</b>	<b>10</b>
2.1 Constituency statements.....	10
2.2 Individual statements .....	10
<b>3 WHA side events.....</b>	<b>12</b>
3.1 The FIP side event held jointly with the IFRC. ....	12
3.2 FIP collaborative side events .....	14
3.3 FIP's contribution to other side events .....	16
3.3.1 FIP advocacy through engagement with Ministry of Health .....	19
3.3.2 FIP advocacy through engagement with key stakeholders .....	21
3.3.3 Key summary notes from the side events .....	26
<b>4 Highlights from the strategic meetings in Geneva.....</b>	<b>31</b>
<b>5 Aligning WHA78 actions with FIP Development Goals and priority programmes.....</b>	<b>32</b>
<b>6 FIP's success at the World Health Assembly: A reflection on the past three years .....</b>	<b>35</b>
<b>7 Conclusions .....</b>	<b>37</b>

# Acknowledgements

FIP would like to acknowledge and thank the following individuals who joined as part of the FIP full delegation attending the 78th World Health Assembly (WHA):

FIP Bureau members: (President) Mr Paul Sinclair AM; (Vice Presidents) Ms Raquel Martines Garcia (Spain), Mr Daragh Connolly (Ireland) and Dr Virginia Olmos (Uruguay); and, (Professional Secretary) Mr Luís Lourenço (Portugal).

Representatives from the FIP constituencies:

- Early Career Pharmaceutical Group (ECPG): Ms Marwah Abdulkarim (Denmark), Ms Chawanya Songthep (Thailand), Ms Ezapue Alexis Ebube (Nigeria), Ms Dilba Nudem Onatli (Sweden) and Ms Yi Ling Ng (Malaysia)
- Community Pharmacy Section (CPS): Mr Sherif Guorgui (Canada)
- Health & Medicines Information Section (HaMIS): Mr Boyan Todorov (Switzerland)

Representatives from FIP member organisations:

- Dr Wael Ali (EOP), Dr Micheal Hogue (APhA), Dr Martine Ruggli (Swiss Pharmacists Association), Mr Mark Koziol (PDA), Ms Katarina Fehir Sola (EPHEU), Mr Norbert Valecka (EPHEU), Mr Andreas May EPHEU, Mr Aris Prins (KNMP), Ms Susan O'Dwyer (IPU), Dr Sharifa AlFajri (Kuwait Pharmaceutical Association), Dr Charlie Yuh-Lih Chang (TSHP), Mr Jack Shen Lim (MPS), Mr Tom Simpson (AdPha), Mr Ricardo Santos (AFPLP), Prof. Helder Mota-Filipe (Portuguese Pharmaceutical Society) and Dr Nenad Miljković (EAHP).

FIP extends its sincere appreciation to the aforementioned delegates for their active participation in WHA78 and invaluable support in preparing the side event reports.

This report was developed by FIP staff members, Dr Aysu Selçuk, FIP Development Goals Lead, Dr Ozge Ozer, FIP Congress Programme and Provision Manager, and Dr Mariet Eksteen, Head of Advocacy, Communications and Marketing, and edited by Dr Catherine Duggan, FIP CEO.

FIP would like to acknowledge that this report was co-created with the input of the FIP full delegates and the Early Career Pharmaceutical Group (ECPG). Moreover, we would like to thank Ms Carola van der Hoeft, FIP COO for her support and preparation of the FIP side event.

We would like to express our sincere thanks to the International Federation of Red Cross and Red Crescent Societies (IFRC) for providing an amazing venue at the headquarters for the FIP side event.

The FIP team would like to extend their thanks to the entire FIP team with special mention to Dr Inês Nunes da Cunha, FIP Practice Development and Transformation Projects Manager, Ms Farah Aqqad, FIP Data Intelligence Lead, and Dr Zuzana Kusynova, FIP Head of Policy and Compliance, for all their support during the preparations for the WHA. In addition, to Ms Laila Ghorab, FIP Communications Manager, for supporting WHA78 advocacy, as well as the Programme Team and Global Pharmaceutical Observatory Team for drafting the individual statements of the WHA78.



## Foreword by FIP President

Dear FIP Members,

We are delighted to present this report on our contribution to the 78th World Health Assembly (WHA) during May 2025. Our attendance enables us to foster our relationship with the World Health Organization (WHO), and provides an opportunity to witness, network, and influence global health policies while championing the invaluable role of pharmacists, pharmaceutical scientists and educators in global health. There is no other event globally that allows FIP to reach out to senior politicians, policymakers and Chief Executive Officers (CEOs) at the various side events organised parallel to the Assembly, which gives FIP delegates an unmatched opportunity to advocate for our profession.

FIP has been in an official relationship with WHO since its inception in 1948, a relationship which has been a cornerstone of our engagement and advocacy on the global health stage. In 2019, this relationship was elevated when FIP signed a Memorandum of Understanding with WHO, governing the next chapter of our collaborations. FIP's non-governmental organisation status allows it to actively participate in meetings of WHO's governing bodies, including the WHA and related side events. This unique opportunity enables FIP to articulate its position and advocate for matters of profound importance to global health, where pharmacy and pharmacists make critical contributions alongside other key stakeholders.


Being part of FIP's delegation in Geneva for the first time, it was particularly special as FIP hosted its side event around the theme of "Pharmacists and Pharmacy – Evidence-based solutions to global threats". The event addressed several important programmes of work where FIP's focus is on highlighting the contribution that pharmacists make to global health. The value of face-to-face interaction with colleagues from all the health disciplines is invaluable during the course of the WHA and our event. It creates opportunities and strengthens existing professional relationships.

Secondly, it was a milestone to launch the cover page image of the Global Situational Report on Pharmacy, along with several advocacy tools in the form of postcards, highlighting key points from the report. The postcards were ideal for use as handouts, conversation starters, or evidence to support a point when addressing colleagues and other healthcare professionals and were well received by all delegates. Furthermore, this advocacy supports the 'Think Health, Think Pharmacy' campaign that was launched at the WHA in 2024, reminding governments and policymakers that whenever they think of health, they should think about pharmacy. We look forward to the launch of the full report at the FIP World Congress in Copenhagen later this year.

In summary, the teamwork among delegates and staff was inspiring. The preparations by FIP staff of all logistics made the task of advocacy and networking by all our delegates very efficient and effective. A big thank you to everyone!

Forward with Pharmacy, Forward with FIP!

Paul Sinclair, AM  
FIP President



## Foreword by FIP CEO

Dear FIP Members,

It is with great pleasure that we present this report capturing our collective engagement at the 78th World Health Assembly (WHA78). Once again, the Assembly highlighted the value of our official relations with the World Health Organization (WHO) by affirming that pharmacists, pharmaceutical scientists and educators are essential partners in advancing global health.

At WHA78, the official FIP delegation delivered ten formal statements spanning critical agenda items—from non-communicable diseases and mental health to substandard and falsified medical products, antimicrobial resistance, pandemic preparedness, workforce sustainability, women's and children's health, emergency response, digital health, and the prevention of violence. Across every intervention, we highlighted how pharmacists expand access, safeguard medicines, and strengthen resilient, people-centred health systems. Through the call for "Think Health, Think Pharmacy" we reminded ministers, partners and stakeholders that the pharmacy profession is an essential ingredient of Universal Health Coverage (UHC).

Our contributions were, as ever, underpinned by the FIP Development Goals, global workforce surveillance, regional AMR roadmaps, FIP's programmes of work, and our upcoming strategic plan, demonstrating the breadth of evidence and tools we bring to policy dialogue. By engaging in high-level discussions, bilateral meetings and side events, our delegates forged new partnerships, advanced the profession's visibility, and influenced resolutions that will guide Member States in the years ahead.

WHA78 also reinforced the urgency of investing in a sustainable, equitably distributed pharmacy workforce. FIP will intensify its support to members and governments, advocating for ethical recruitment, robust education pathways and the full integration of pharmacists into national health strategies.

This report is both a record of achievement and a platform for future action. I invite you to draw on its insights to inform your own advocacy and to identify opportunities for collaboration with us. Together we will continue to demonstrate that empowering pharmacists is a direct investment in healthier communities and more resilient health systems.

Thank you for your commitment to FIP's mission and for the passion you bring to our shared work. Let us build on the momentum of WHA78 as we strive to leave no one behind, by advancing pharmacy worldwide through universal pharmacy coverage.

Dr Catherine Duggan  
FIP Chief Executive Officer



## Executive summary

The 78th World Health Assembly (WHA) marked a significant moment for the International Pharmaceutical Federation (FIP), with impactful participation from its dedicated delegation. The FIP delegation was composed of 33 committed individuals, including members of the FIP Bureau, the Chief Executive Officer, representatives from Member Organisations (MOs), various FIP constituencies, the Early Career Pharmacy Group (ECPG), and staff members from the FIP headquarters.

FIP delivered ten individual statements and three constituency statements to the World Health Organization (WHO) Member States, advocating for the role of pharmacists in addressing key global health priorities, including antimicrobial resistance (AMR), workforce development, social determinants of health, and women's, children's and adolescents' health, emergency prevention and preparedness, climate change, primary health care, and universal health coverage. These interventions are closely aligned with FIP's priority programmes, vision and mission.

During WHA78, FIP hosted its own side event on 20 May 2025, entitled "Pharmacists and pharmacy: Evidence-based solutions to global threats", at the headquarters of the International Federation of Red Cross and Red Crescent Societies (IFRC). This high-level session highlighted FIP's leadership in areas such as pharmacy-based vaccination, humanitarian response, and sustainable and digital pharmacy practice.

Beside the statements and FIP side event, FIP launched a new infographic mapping our proposed actions for transforming pharmacy to support resilient health systems. This infographic is a call to action for pharmacists and presents proposed actions to our stakeholders.

FIP also co-hosted two side events organised by the World Health Organization (WHO) and Taiwan Society of Health-System Pharmacists (TSHP). FIP Bureau members spoke at five side events organised by the World Health Professions Alliance (WHPA), World Heart Federation (WHF), International Patients' Union and Health Parliament, Global Action on Men's Health, and Global Self-Care Federation (GSCF). FIP's participation underscored its continued commitment to advocating for the pharmacy profession at the highest level of global health governance. By voicing the needs and perspectives of its global network, FIP ensured that pharmacy's contributions to public health, access to medicines, and health workforce sustainability were recognised and valued by international stakeholders.

Strategic meetings were also held to support collaboration and strengthen relationships with key health stakeholders including WHO Headquarters, WHO Academy, European Association of Employed Pharmacists (EPHEU), and the Association of Pharmacists of Portuguese-Speaking Countries (AFPLP). Advocacy, alignment, and collaboration emerged as the central themes of these meetings, guiding the discussions and reinforcing the importance of united action in advancing global health goals.

This report is divided into several sections, each highlighting different aspects of FIP's participation at the 78th WHA.

# 1 FIP Delegation at WHA78

The 78th World Health Assembly (WHA) was held in Geneva, Switzerland, on 19–27 May 2025. The theme of this year's Health Assembly was **One World for Health**.

Director-General Dr Tedros Adhanom Ghebreyesus opened WHA78 with a powerful call to action: adopt the Pandemic Agreement, commit resources, and strengthen global health security in the face of invisible threats. He stressed the importance of unity, accountability, and honouring WHO's legacy—all to safeguard health equity worldwide. He said, "in response to the lessons learned from COVID-19 and other health emergencies, WHO is supporting countries to strengthen their capacities through the Health Emergency Preparedness and Response Framework." WHO is supporting voluntary national and global peer reviews of preparedness through the Universal Health and Preparedness Review.

The WHA78 hosted a series of side events including [47 official events at Palais de Nations](#). These side events covered various topics in line with the [14th Global Programme of Work of WHO](#): i) respond to climate change, an escalating health threat; ii) address determinants of health and root causes of ill health; iii) advance the primary healthcare approach and essential health system capacities for universal health coverage; iv) improve health service coverage and financial protection; v) prevent, mitigate and prepare for health risks from all hazards; and, vi) rapidly detect and sustain response to health emergencies.

Recordings of the WHA78 sessions can be accessed through the following link: [78th World Health Assembly](#) and the agenda is available [here](#).

## 1.1 FIP delegation at WHA78

During the World Health Assembly, FIP had two types of delegates: full delegates and official delegates. The World Health Organization (WHO) had imposed a limit of accepting a maximum of six official delegates per non-State actor (NSA). While the number of **official delegates** from FIP was restricted by WHO regulations, there were additional avenues for engagement and influence beyond direct WHA participation.

The WHA serves as a prominent global gathering, bringing together health ministers, governmental authorities, health policymakers, health-related NGOs, industry representatives, and WHO policy and technical officers. Alongside the WHA, numerous meetings and side events were held in various locations across Geneva, offering opportunities for networking and influencing policymaking. These events, though less formal and on a smaller scale, provided valuable avenues for engagement.

The FIP delegation had **official delegates** playing a vital role in the WHA proceedings while the **full delegation** included a broader representation of FIP leadership, team members, and member organisations, fostering engagement and collaboration with key stakeholders.

The **official FIP delegation** comprised the WHO limit of five delegates including two representatives from the FIP Early Career Pharmaceutical Group (ECPG) and three FIP team members. These official delegates actively participated in the WHA meetings, delivering pre-scripted and agreed-upon statements on behalf of FIP. They were given badges granting access to the United Nations' buildings (Palais des Nations) and were able to contribute to strategic roundtables and events held at the Palais des Nations.

Pictured below are the FIP official delegates. From left to right: Dilba Nudem Onatli (FIP Early Career Pharmaceutical Group), Ozge Ozer (FIP HQ), Aysu Selçuk (FIP HQ), Mariet Eksteen (FIP HQ), and Yi Ling Ng (FIP Early Career Pharmaceutical Group).





FIP Official delegation

The **full FIP delegation** comprised the FIP CEO, three FIP team members, Bureau vice presidents, FIP Member Organisations (MOs) and section presidents, ECPG, and interested member organisations. This inclusive approach provided member organisations with a valuable opportunity to engage with their respective countries' representatives, ministers, and WHO officials, fostering meaningful interactions during the WHA side events and receptions.



Members of the FIP full delegation at the FIP meet-and-greet event

Table 1 presents the delegates who represented FIP at the WHA. The full FIP delegation consisted of a total of 33 delegates, including five official delegates who attended the WHA sessions (marked with a \*).

Table 1. FIP-WHA78 full delegates

Delegate name	Affiliation and role
Mr Paul Sinclair AM	FIP President
Dr Catherine Duggan	FIP Chief Executive Officer
Ms Raquel Martinez Garcia	FIP Vice President
Dr Virginia Olmos	FIP Vice President
Mr Luís Lourenço	FIP Professional Secretary
Ms Carola van der Hoeft	FIP Chief Operating Officer
Dr Daragh Connolly	FIP Chair, Board of Pharmaceutical Practice, Irish Pharmacy Union (IPU)
Mr Sherif Guorgui	President, Community Pharmacy Section
Mr Boyan Todorov	FIP Health and Medicines Information Section (HaMIS)
Dr Wael Ali	Egyptian Organization of Pharmacy (EOP) & Vice President of FIP EMRpharm Forum
Dr Micheal Hogue	American Pharmacists Association (APhA)
Dr Martine Ruggli	Swiss Pharmacists Association
Mr Mark Koziol	Pharmacists' Defence Association (PDA)
Dr Mariet Eksteen *	FIP Head of Advocacy, Communications and Marketing
Dr Aysu Selçuk*	FIP Development Goals Lead
Dr Ozge Ozer *	FIP Congress Programme and Provision Manager
Ms Dilba Nudem Onatli*	FIP Early Career Pharmaceutical Group (ECPG)
Ms Yi Ling Ng*	FIP Early Career Pharmaceutical Group (ECPG)
Ms Marwah Abdulkarim	FIP Early Career Pharmaceutical Group (ECPG)
Ms Chawanya Songthep	FIP Early Career Pharmaceutical Group (ECPG)
Ms Ezapue Alexis Ebube	FIP Early Career Pharmaceutical Group (ECPG)
Ms Katarina Fehir Sola	European Association of Employed Pharmacists (EPHEU)
Mr Norbert Valecka	European Association of Employed Pharmacists (EPHEU)
Mr Andreas May	European Association of Employed Pharmacists (EPHEU)
Mr Aris Prins	Royal Dutch Pharmacists Association (KNMP)
Dr Sharifa AlFajri	Kuwait Pharmaceutical Association
Mr Jack Shen Lim	Malaysian Pharmacists Society (MPS)
Mr Tom Simpson	Advanced Pharmacy Australia (AdPha)
Mr Ricardo Santos	Association of Pharmacists of Portuguese-Speaking Countries (AFPLP)
Ms Susan O'Dwyer	Irish Pharmacy Union (IPU)
Prof. Helder Mota-Filipe	Portuguese Pharmaceutical Society
Dr Charlie Yuh-Lih Chang	Taiwan Society of Health System Pharmacists
Dr Nenad Miljković	European Association of Hospital Pharmacists

\*FIP official delegates

## 1.2 FIP-WHA78 delegates' testimonials

Delegates shared several highlights from their presence in Geneva during WHA78 and attendance at side events as part of the FIP delegation:

- “Being able to engage in high-level discussions and advocate for the role of pharmacists and pharmaceutical scientists in strengthening health systems.”
- “Witnessing pharmacists from around the world come together to represent our profession across a wide range of sectors and engage with them in person, instantly.”
- “Pharmacists are being recognised as key players in the global response to climate change and public health threats.”
- “A strong sense of unity and purpose was felt when standing alongside fellow members of FIP.”
- “Ability to make key connections with other NGOs from one's country, which will prove invaluable in the coming months working on national priorities.”
- “The variety of side events hosted during this week brought attention to many crucial and often overlooked aspects of patient care.”

- “Participating in the WHA has been a great opportunity for me, as a representative of my national pharmacist organisation, to get a better understanding of the functioning and the key areas of work of the WHO and the importance of building a good relationship between FIP and WHO and its impact on the pharmaceutical profession.”

“Our unified presence in Geneva—combined with the shared concern over the lack of pharmacy inclusion in major healthcare initiatives—underscored a universal demand: the urgent need to strengthen and recognise the role of pharmacists within health systems. This collective voice was both inspiring and a reminder of the global momentum behind advancing our profession.”  
Sharifa Al-Fajri, Kuwait Pharmaceutical Association

Delegates shared positive feedback following the FIP side event (see section 4.1):

- “The FIP-led event was most enriching, offering both strategic insight and a clear vision for our profession’s future.”
- “Witnessing how pharmacists are shaping evidence-based responses to global health threats from antimicrobial resistance (AMR) to humanitarian crises.”
- “Many influencers, officials and healthcare leaders left this event knowing a lot more about what pharmacists can offer.”
- “The formal advocacy side event where FIP showcased the less obvious but nonetheless ambitious pharmacy achievements was a particularly powerful event. FIP should repeat this at next year’s WHA.”
- “It was very enriching to be part of the discussion about pharmacists’ role on key public health issues such as AMR, pharmacy-based vaccination, non-communicable diseases, medication adherence or sustainable pharmacy.”

“WHA78 reminded me that we are not just future leaders—we are leaders now.”  
Chawanya Songthep, External Affairs Chairperson, Asian Young Pharmacists Group

“Engaging with global leaders and youth delegates across sectors affirmed that pharmacy belongs not just at the counter, but at every decision-making table.”  
Alexis Ezepue, Early Career Pharmaceutical Group (ECPG)

FIP’s presence at the WHA with a full delegation—not just a few staff members—is crucial because it ensures that diverse voices and expertise from across the pharmacy profession are represented. A broad delegation allows for meaningful engagement in multiple sessions, networking with global health leaders, and advocating effectively for pharmacists at all levels, from student and early career professionals to seasoned experts. This diversity strengthens FIP’s influence in shaping health policies, building partnerships, and promoting the critical role pharmacy plays in achieving universal health coverage (UHC) and addressing global health challenges. Delegates agreed:

- “A full delegation ensures that pharmacy is represented in its true diversity across regions, generations, and areas of expertise.”
- “As a young pharmacist, my lens differs from a policymaker or a scientist, but all are vital to shaping global advocacy.”
- “Attending as a full delegation amplified pharmacy’s voice across multiple side events, informal networking, and parallel youth movements.
- “It reflects the diversity of our profession—spanning practice, science, and education—and strengthens our global presence.”
- “With so many side events occurring simultaneously across Geneva, to have the desired impact, FIP representatives need to be spread across several venues at any one time. This requires larger numbers being present at the event, but for sure, the results are worth the effort.”
- “Given the many meetings and side events that are happening during the WHA, I think it is important for FIP’s and pharmacist’s visibility to participate with a full delegation in order to be as much present as possible.”

“One of the comments that I received at one of the side events I attended was ‘You pharmacists are everywhere’. This augurs well.”

Mark Koziol, Pharmacists Defence Association

“WHA is comprised of dozens of side events, most of which are more important in many ways than the WHA itself. It would be impossible for FIP staff alone to cover the key side events and read our statements into the Assembly. Having a broad range of FIP representatives from the Bureau and Council gave the profession the visibility it so rightly deserves.”

Michael Hogue, American Pharmacists Association

### The FIP meet-and-greet event

FIP CEO, Dr Catherine Duggan, invited all delegates to a meet-and-greet event. This took place on 19 May 2025 at 10am at Hotel Royal’s Bistro. The purpose of this event was, firstly, to provide an opportunity for delegates representing FIP constituencies and Member Organisations to get to know each other, and the FIP Bureau members and staff. This networking opportunity is crucial for delegates to learn from one another, foster relationships, and explore future collaboration possibilities.

During the meet-and-greet, the advocacy tools were introduced and distributed to delegates. This year, two specific approaches to advocacy were introduced, both related to the anticipated launch of the Global Situational Report on Pharmacy. This publication will highlight the global situation regarding various aspects relevant to pharmacy and pharmacists. From this report, important snippets were extracted to compile a set of twelve different postcards highlighting unique contributions made by pharmacists, based on data and evidence, with relevant references. Additionally, the front and back cover of the report were printed out, making them ideal for photo opportunities and conversation starters.



From left: Michael Hogue (American Pharmacists Association), with Catherine Duggan (FIP CEO) and Aris Prins (Royal Dutch Pharmacists Association), at the meet-and-greet event.

## 2 FIP interventions at WHA78

The participation of FIP at the 78th WHA was marked by a series of impactful statements that reflected FIP's commitment to advancing pharmacists' contributions to addressing global health priorities. These statements included both individual statements, where FIP representatives presented FIP's perspective on specific agenda items, and constituency statements, which involved collaborative efforts with partner organisations and alliances.

In this section, we highlight the statements delivered by FIP at WHA78 and their relevance to our FIP priority programmes (Tables 2 and 3).

### 2.1 Constituency statements

Table 2. FIP-WHA78 constituency statements

	Agenda item	Alignment to FIP Priority Programme(s)
1	<a href="#">Agenda item 13.3 Universal health coverage: Primary health care</a>	Primary health care programme
2	<a href="#">Agenda item 16.1 Strengthening the global architecture for health emergency prevention, preparedness, response and resilience</a>	Humanitarian programme
3	<a href="#">Agenda item 18.3 Climate change and health</a>	Sustainability in pharmacy programme

### 2.2 Individual statements

Table 3. FIP-WHA78 individual statements

	Agenda item	Alignment to FIP Priority Programme(s)
1	<a href="#">Agenda item 13.1 Follow-up to the political declaration of the third high-level meeting of the General Assembly on the prevention and control of non-communicable diseases</a>	Non-communicable diseases programme (NCDs)
2	<a href="#">Agenda item 13.2 Mental health and social connection</a>	Non-communicable diseases programme (NCDs); Self-care & management of common ailments
3	<a href="#">Agenda item 13.5 Substandard and falsified medical products</a>	Patient safety programme
4	<a href="#">Agenda item 13.7 Health and care workforce</a>	Multinational needs assessment and surveillance programme
5	<a href="#">Agenda item 13.9 Global strategy for women's, children's and adolescents' Health</a>	Equity & equality programmes (including FIPWiSE)
6	<a href="#">Agenda item 15. Antimicrobial resistance</a>	Antimicrobial stewardship programme
7	<a href="#">Agenda item 16.2 Intergovernmental Negotiating Body to draft and negotiate a WHO convention, agreement or other international instrument on pandemic prevention, preparedness and response</a>	Humanitarian programme
8	<a href="#">Agenda item 28. 1 C. Integrated emergency, critical and operative care for universal health coverage and protection from health emergencies (resolution WHA76.2 (2023))</a>	Humanitarian programme
9	<a href="#">Agenda item 24.2 D. Global strategy on infection prevention and control (resolution WHA75.13 (2022))</a>	Disease prevention programme, Antimicrobial stewardship programme
10	<a href="#">Agenda item 24.3 L. WHO global plan of action to strengthen the role of the health system within a national multisectoral response to address interpersonal violence, in particular against women and girls, and against children (resolution WHA69.5 (2016)) a</a>	Equity & equality programmes (including FIPWiSE)



Pictured below are the FIP official delegates as they deliver their individual statements on behalf of FIP during the WHA78.

Dilba Onatli from the FIP Early Career Pharmaceutical Group (ECPG) delivering FIP's statement on *Intergovernmental Negotiating Body to draft and negotiate a WHO convention, agreement or other international instrument on pandemic prevention, preparedness and response*



Ozge Ozer from the FIP team delivering FIP's statement on *Global strategy on infection prevention and control (resolution WHA75.13 (2022))*



Yi Ling Ng from the FIP Early Career Pharmaceutical Group (ECPG) delivering FIP's statement on *Follow-up to the political declaration of the third high-level meeting of the General Assembly on the prevention and control of non-communicable diseases*



Aysu Selçuk from the FIP team delivering FIP's statement on *Integrated emergency, critical and operative care for universal health coverage and protection from health emergencies (resolution WHA76.2 (2023))*



## 3 WHA side events

### 3.1 The FIP side event held jointly with the IFRC

FIP also hosted its own side event on 20 May 2025, entitled **“Pharmacists and pharmacy: Evidence-based solutions to global threats”** at the headquarters of the International Federation of Red Cross and Red Crescent Societies (IFRC).


This high-level session highlighted FIP’s leadership in the following topics:

- Vaccination for all: Recognising the pharmacist’s role in life course immunisation
- Expanding pharmacy’s role in non-communicable diseases and community self-care
- Addressing antimicrobial resistance through policy, stewardship, and the One Health approach; Response: International Committee of the Red Cross (ICRC)
- Enhancing access and equity: The role of pharmacy in supply chain leadership; Response: International Committee of the Red Cross (ICRC)
- Pharmacists on the frontlines: Responding to humanitarian crises, climate change, and communicable diseases; Response: International Federation of Red Cross and Red Crescent Societies (IFRC)
- Strengthening the global pharmacy workforce: Progress, challenges, and the path ahead.

The presentation was followed by a panel discussion. The panellists, including the Minister of Health of Portugal, Ambassador of Global Health, and colleagues from WHO, IFRC and the Swiss Tropical and Public Health Institute, reinforced the importance of cross-sector collaboration, spotlighting opportunities for partnership with the IFRC in emergency response and support for the WHO’s National Health Workforce Accounts. The message was clear: pharmacists are indispensable allies in tackling global health challenges.



The FIP President shares his opening remarks at the FIP side event



The FIP CEO moderates the panel discussion at the FIP side event







Participants at the FIP side event



### 3.2 FIP collaborative side events

Table 4. FIP co-organised side events

	Title, organiser and date	Topic and/or summary	Images
1	<p>Global Pharmaceutical Forum on Medication Supply</p> <p><b>Organiser:</b> Taiwan Society of Health-System Pharmacists (TSHP)</p> <p><b>Co-host:</b> FIP</p> <p>21 May 2025</p>	<p>This session brought together experts from Taiwan and international organisations to share insights and strategies on addressing global drug supply shortages. The forum concluded with a strong consensus on the urgent need for greater regional and international cooperation to mitigate medication shortages and supply disruptions. Speakers highlighted that resilient supply chains require not only diversified manufacturing and procurement strategies, but also regulatory convergence and transparent communication between stakeholders. The panel discussion underscored the importance of investing in digital traceability systems, building regional stockpiles, and enhancing the role of pharmacists in emergency preparedness and response. Participants agreed that sustainable solutions must integrate policy innovation, workforce development, and collaboration among governments, industry, and professional bodies to secure global medicine access in an increasingly volatile environment.</p>	   


		 
<p>2 The contribution of self-care to advance sexual and reproductive health and rights</p> <p><b>Organiser:</b> WHO <b>Co-host:</b> FIP</p> <p>23 May 2025</p>	<p>We are experiencing a pivotal moment in advancing sexual and reproductive health and rights (SRHR) through the growing movement of self-care. Globally, individuals are increasingly taking ownership of their health, seeking reliable information and trusted guidance to support informed decisions. Various representatives from MoHs and NGOs joined the event to share experiences and future directions. For self-care to succeed globally, we must ensure that tools and information are accessible everywhere. With vigilance, evidence-based policies, and collective commitment, self-care can be a path to better health, equality, and resilience.</p>	 



### 3.3 FIP’s contribution to other side events

FIP spoke in five side events as speakers and panellists. A short summary of these is demonstrated in Table 5.





Table 5. FIP’s contribution to side events

	Title, organiser and date	Topic and/or summary	Images
1	<p>Digital health without borders</p> <p><b>Organiser:</b> International Patients’ Union and Health Parliament</p> <p>19 May 2025</p>	<p>Despite rapid advancements in healthcare technology, 4.5 billion people still lack access to its benefits, according to the WHO. This new initiative seeks to bridge that gap. The launch will feature the unveiling of the Geneva Declaration of Responsibility and a high-level dialogue on digital health diplomacy, ethical data sharing, and cross-border collaboration. Pharmacists and nurses play a critical role in turning this vision into reality, and their engagement is essential to the initiative’s success.</p>	

		
2	<p>Empowering self-care: Digital innovations for NCD prevention and management</p> <p><b>Organiser:</b> GSCF and Be He@lthy Be Mobile, a joint initiative of the World Health Organization (WHO) and the International Telecommunication Union (ITU)</p> <p>19 May 2025</p>	<p>Digital innovation plays a vital role in empowering self-care for the prevention and management of non-communicable diseases (NCDs). To scale up effective, people-centred solutions, strong collaboration between the health and technology sectors is essential. Cross-sector partnerships can drive innovation, improve access, and enhance the impact of digital tools in supporting individuals to take charge of their health.</p>  

			
3	<p>Rising challenges, diminishing resources: Safeguarding the health workforce to deliver UHC</p> <p><b>Organiser:</b> WHPA</p> <p>19 May 2025</p>	<p>Health workforce migration is a complex global issue that extends beyond a simple flow from low-income to high-income countries. While many developing nations experience significant emigration of healthcare professionals, countries like the USA and Norway export very few doctors. In contrast, the UK trains fewer doctors than it exports each year—a clearly unsustainable trend.</p> <p>A key driver of migration is the lack of adequate protections, benefits, and employment opportunities in some countries, prompting professionals to seek better conditions abroad. To address this imbalance, there is a growing call for high-income countries to compensate source countries, potentially through bilateral trade agreements.</p> <p>A more sustainable and equitable model is circular migration, where professionals—such as a doctor trained in the Philippines—gain experience abroad (e.g., in the UK) and return home with enhanced skills. This principle applies not only to doctors but also to nurses, and should be encouraged as part of global workforce strategies.</p>	 
4	<p>Better adherence, better control, better health</p>	<p>Adherence is crucial for achieving better health outcomes and improving quality of life. Even the most effective medicine is useless if not taken properly. Digital tools can play a</p>	



<p><b>Organiser:</b> World Heart Federation (WHF)</p> <p>20 May 2025</p>	<p>vital role in supporting treatment adherence, particularly in remote areas, by enabling monitoring and communication. Rather than emphasising "better control," focusing on positive, patient-centred language can encourage better engagement. Ultimately, two-way communication between patients and healthcare providers is key to improving adherence and promoting better health.</p>	 
<p>5 Men, cancer and HPV: New perspectives on prevention</p> <p><b>Organiser:</b> Global Action on Men's Health</p> <p>20 May 2025</p>	<p>The roundtable aimed to raise awareness about the global impact of cancer on men and emphasised the need for a policy response. Key topics included the potential of gender-neutral HPV vaccination (GNV) to reduce cancer incidence and mortality in both sexes, lessons from single-sex vaccination programmes, and opportunities for GNV in Africa. Participants were informed about the Global Call for Action on GNV and explored collaboration opportunities. They suggested concrete strategies and recommendations to advance GNV, and support advocacy efforts planned for 2025, particularly in low- and middle-income countries.</p>	 

### 3.3.1 FIP advocacy through engagement with Ministry of Health

Advocacy through active engagement with the Ministry of Health is essential to influence policy, secure support for sustainable solutions for pharmacy, and ensure that our needs are heard and prioritised in national health strategies.

Therefore, FIP consistently seeks opportunities to engage with Ministries of Health and other key partners. WHA is a perfect event for such opportunities.

Ng Yi Ling and Dilba Onatli (FIP Early Career Pharmaceutical Group) with Jennifer Carroll MacNeill TD, Minister for Health, Ireland



Aysu Selcuk (FIP Development Goals Lead) and Dilba Onatli (FIP Early Career Pharmaceutical Group) with Jo Etienne Abela, Minister for Health and Active Ageing, Malta



Jack Shen Lim (Malaysian Pharmacists Society) and Ng Yi Ling with Dr Dzulkefly Ahmad, Malaysian Minister of Health, Malaysia



FIP head of advocacy, communications and marketing, Mariet Eksteen, with Nonhlanhla Makhanya, South African Chief Nurse and Midwifery officer



Dilba Onatli (FIP Early Career Pharmaceutical Group) with Salina Grenet-Catalana, Ministry of Europe Foreign Affairs

Tom Simpson (Advanced Pharmacy Australia) with Austria's Chief Medical Officer, Prof. Michael Kidd





Ng Yi Ling and Dilba Onatli (FIP Early Career Pharmaceutical Group) with Philippine Department of Health Secretary, Teodoro J. Herbosa



FIP staff with Dr Esperance Luvindao, Minister of Health and Social Services, Namibia



### 3.3.2 FIP advocacy through engagement with key stakeholders

FIP delegates participated in over 60 side events at WHA78, actively advocating for the vital role of pharmacists in health systems. A selection of images from WHA78 can be found below:

















### 3.3.3 Key summary notes from the side events

During the 78th World Health Assembly, FIP delegates actively participated in over 60 side events, contributing to high-level discussions on global health priorities. These sessions provided critical opportunities to advocate for the role of pharmacists and highlight their contributions to achieving universal health coverage and strengthening health systems. FIP's active presence ensured that the pharmacy profession was represented in a wide range of discussions, reinforcing our commitment to advancing global health through innovation, collaboration, and advocacy.

Table 6. Key takeaways from the side events

Date	Event name	Key takeaways
18 May 2025	Enhancing collaboration and solutions for health workforce migration: Strengthening global health systems for UHC	<p>The session addressed the critical and complex issue of healthcare workforce migration, underscoring the urgent need for ethical, equitable, and sustainable systems that benefit both source and destination countries.</p> <p>Key messages included:</p> <ul style="list-style-type: none"> <li>• Ethical migration frameworks must be in place to ensure healthcare worker movement is mutually beneficial, supports learning opportunities, and respects both the aspirations of individuals and the needs of health systems.</li> <li>• Equity and fairness in remuneration, recognition, and working conditions are vital to retain and respect healthcare professionals.</li> <li>• Migration affects all health professions, not just doctors. With a global physician shortage, the greatest exodus is from African countries, driven by economic pressures, lack of fairness, and poor living conditions.</li> <li>• Countries must focus on building resilient health systems, improving working conditions, and reducing push factors for migration.</li> <li>• The International Labour Organization (ILO) has developed guidelines to protect health workers and promote ethical recruitment.</li> </ul>
19 May 2025	Introduction to the 78th World Health Assembly: Critical perspectives on multilateralism in global health in 2025	<p>A dedicated panel explored the role of NGOs in shaping global health governance. The discussion highlighted WHO's continued efforts to strengthen NGO involvement, recognising their essential contributions to inclusive and responsive health systems.</p> <p>While broad inclusion is encouraged, participants stressed the need for clear regulatory frameworks to ensure accountability, transparency, and coherence within the global health architecture. The panel acknowledged that this is a complex and evolving process requiring ongoing dialogue and refinement.</p>
19 May 2025	ECO continuum: How ACAN is driving better patient outcomes	<p>The session highlighted the importance of ensuring patients receive fundamental, high-quality care, starting with better training and support for healthcare providers. While providers may have the intention to help, system-level support is often lacking.</p> <p>The Acute Care Action Network (ACAN) can play a critical role by:</p> <ul style="list-style-type: none"> <li>• Providing adaptable care models, such as low-cost ICU training</li> <li>• Advocating for bundled funding approaches to support holistic patient care</li> <li>• Promoting unified patient record systems to better track and coordinate care.</li> </ul> <p>ACAN's platform also offers a means to amplify healthcare professionals' voices, reinforcing the message that system integration and collaboration save lives.</p>
19 May 2025	Unlocking the value of 'Women and health' - A paradigm shift for equity, innovation and sustainable impact	<p>The session called for urgent action to address these disparities through gender-responsive research, early detection efforts, and policy reform to improve access to diagnostic services for women worldwide.</p> <p>Key issues highlighted include:</p> <ul style="list-style-type: none"> <li>• Only 2% of cancer research is focused specifically on women</li> </ul>

		<ul style="list-style-type: none"> <li>An estimated 80,000 women die annually from cancers that could have been detected earlier</li> <li>Access to mammography remains limited in many settings due to outdated prescription requirements.</li> </ul>
19 May 2025	The collaborative role of the global patient organisation community in advancing social participation for UHC	<p>The session emphasised the need for governments to institutionalise social participation to ensure health policies and services are responsive to the real needs of communities, particularly marginalised populations.</p> <p>Key messages included:</p> <ul style="list-style-type: none"> <li>Patients and civil society must have a formal role in health policymaking through representation at decision-making tables.</li> <li>Community engagement should be recognised and invested in as a strategic tool to improve health outcomes and foster accountability.</li> </ul> <p>Strengthening inclusive governance in health systems is essential for building trust, equity, and more effective services.</p>
19 May 2025	Airways ahead: Breathing new life into policy for lung health	<p>The session highlighted COPD and asthma as priority lung diseases for the WHO, given their high prevalence and treatability. With over 500 million people affected globally, effective management through primary care is essential for timely diagnosis, referral, and treatment.</p> <p>It is acknowledged that pharmacists have critical role in supporting care for these conditions.</p> <p>Key challenges discussed included:</p> <ul style="list-style-type: none"> <li>COPD as the fourth leading cause of death worldwide</li> <li>Inequitable access to essential medications: only 60% of low- and middle-income countries have reliable access to beta agonists and steroid inhalers</li> <li>Limited availability of diagnostic tools like peak flow meters, accessible in only 20–25% of settings.</li> </ul> <p>The discussion reinforced the need for stronger primary care infrastructure, equitable resource distribution, and the inclusion of pharmacists to improve respiratory health outcomes.</p>
19 May 2025	Protecting one billion hearts: Partnering to accelerate access to heart-saving medicines	<p>The session highlighted that closing the treatment gap in hypertension care requires global collaboration and scalable, data-driven national strategies. Achieving the WHO's global targets—80% awareness, 64% treatment, and 51% control—depends on robust health information systems, consistent access to essential medicines, and inclusive care delivery models.</p> <p>Korea's experience was highlighted as a successful example, demonstrating how political commitment and well-structured national programmes can lead to significant improvements in blood pressure control at the population level.</p>
19 May 2025	Unlocking the potential of self-care in the fight against NCDs	<p>The session emphasised the urgent need to integrate self-care into national health systems, starting with inclusion in policies, enhanced collaboration, and effective information exchange. Participants called for structured implementation pathways that empower individuals and strengthen preventive care.</p> <p>Key messages included:</p> <ul style="list-style-type: none"> <li>Stakeholders were encouraged to review and contribute to the open consultation for The Zero Draft Political Declaration .</li> <li>Many risk factors for NCDs emerge in childhood, underscoring the importance of early intervention.</li> <li>Family planning must remain a priority within comprehensive health strategies.</li> <li>Oral health was highlighted for its often overlooked role in the development and progression of NCDs such as cardiovascular disease and diabetes, due to shared inflammatory pathways.</li> </ul>

		The discussion reinforced the need for holistic, life-course approaches to prevention, with self-care, early action, and multi-sectoral engagement at the core.
20 May 2025	Geneva Health Forum 2025, Malnutrition: The road to 2030 - Building on success, facing what's next	<p>The session explored the complex links between nutrition, immunisation, agriculture, and climate change, highlighting the need for integrated and systemic approaches.</p> <ul style="list-style-type: none"> <li>Improved nutrition leads to better health outcomes, including reduced need for vaccinations and lower disease burden.</li> <li>Food and agricultural systems are closely tied to climate change and must be part of health resilience strategies.</li> <li>There is a growing need for dialogue on the interconnection between nutrition, agriculture, and climate change.</li> <li>Building an integrated nutrition system remains a major challenge, requiring coordinated efforts across sectors.</li> </ul>
20 May 2025	Skin diseases as a global public health priority	<p>This session highlighted the urgent need to improve the management of dermatological conditions within primary care. Despite affecting a large portion of the global population, skin diseases remain under-recognised in global health agendas.</p> <p>Key points included:</p> <ul style="list-style-type: none"> <li>Training the primary care workforce is essential for early detection and effective management, with emphasis on neglected tropical diseases (NTDs) and use of WHO Academy resources.</li> <li>Stigma reduction, integration of skin health into Universal Health Coverage (UHC), and prioritising healthcare worker education were identified as critical steps.</li> <li>Speakers expressed hope for a World Health Assembly resolution to formally recognise skin diseases as a global health priority.</li> </ul> <p>The call for coordinated global action was strongly supported during the closing and networking sessions.</p>
20 May 2025	Implementing primary health care: Building momentum through the Global Coalition of Countries on PHC	<p>Pharmacists are essential to building integrated, people-centred primary health care (PHC) systems. As accessible and trusted professionals, they contribute to essential service delivery, health promotion, medication management, and chronic disease care within communities.</p> <p>The session highlighted aligning pharmacy practice with global goals such as the Sustainable Development Goals (SDGs), Universal Health Coverage (UHC), and pandemic preparedness enhances their impact on achieving equitable and resilient health systems.</p> <p>Strengthening PHC creates opportunities for pharmacists to expand their roles, collaborate in interprofessional teams, and lead local health initiatives—ultimately improving health outcomes, medication adherence, and access to community-based care.</p>
21 May 2025	Climate change and health: Adaptation and resilience in a changing world	<p>This session focused on the growing urgency to address the intersection of climate change and health, highlighting strategic actions and innovations being pursued globally:</p> <ul style="list-style-type: none"> <li>Engaging and educating young people is critical to building long-term awareness and resilience against the climate-health crisis.</li> <li>WHO is working on developing specific guidelines to support climate action in the health sector.</li> <li>Responding with urgency is essential, given the accelerating pace and scale of the climate crisis.</li> <li>Robust evaluation frameworks and clear metrics are essential to support evidence-based policymaking and guide researchers.</li> </ul>

21 May 2025	Health Without Borders: Integrated primary healthcare for all	The session aimed to promote inclusive, integrated primary healthcare (PHC) as a foundation for achieving universal health coverage (UHC), emphasising cross-border collaboration, community empowerment, and inclusive policymaking.
21 May 2025	Transforming the narrative: Chronic respiratory diseases in the HLM4	<p>This session emphasised the urgent need to strengthen primary care systems and ensure equitable access to essential, affordable, and effective medicines—particularly for those living with chronic respiratory diseases (CRDs). With projections indicating that CRDs could cause 60 million deaths by 2040, a call was made to elevate lung health to the same level of policy priority as cancer and heart disease.</p> <p>Key messages included:</p> <ul style="list-style-type: none"> <li>• The responsibility to act is shared, and inaction undermines human dignity.</li> <li>• Health policies must integrate lung health into primary care strategies, with dedicated financing mechanisms.</li> <li>• Special attention is needed for vulnerable groups, especially pregnant women, one-third of whom may face worse outcomes due to inadequate care.</li> </ul>
21 May 2025	HPV gender-neutral vaccination (HPV GNV)	<p>The session highlighted that gender-neutral HPV vaccination is essential for achieving comprehensive and equitable protection against HPV-related cancers. Speakers emphasised that focusing only on girls leaves significant gaps in prevention, perpetuates gender bias, and limits public health impact. Expanding vaccination to all genders not only protects more individuals but also strengthens herd immunity and accelerates progress toward elimination targets.</p> <p>The event concluded with a call to integrate HPV GNV into national immunisation strategies, strengthen health education to combat misinformation, and foster collaboration among governments, civil society, and global health partners to ensure inclusive, science-based, and equitable public health policies, thus accelerating the path to elimination.</p> <p>While the formal agenda did not include specific references to the role of pharmacists, a question posed to the panel at the end of the event led to unanimous agreement among the speakers on the importance of pharmacists in awareness, education, and vaccine delivery. This point was further reinforced in conversations during the final networking session with the event organisers, highlighting the value of involving pharmacists as trusted, accessible healthcare providers in immunisation programmes.</p>
22 May 2025	Addressing the global crisis of substandard and falsified medicines – A panel discussion enhancing the work of WHO Member States mechanism through regional engagement, stakeholder collaboration and operation agility	<p>This session highlighted the increasing global threat posed by substandard and falsified (SF) medicines, particularly through online platforms and informal markets. These products compromise patient safety and erode trust in health systems, especially in low-resource and humanitarian settings. Country responses vary widely. Nigeria has made significant progress through inspections, local manufacturing support, and post-marketing surveillance. The Gambia responded to a national tragedy with a comprehensive plan focusing on institutional reform and imported medicine testing. Indonesia emphasised the importance of international cooperation and regulatory strengthening.</p>
23 May 2025	Addressing paediatric non-communicable diseases: Building systems-based approaches in nutrition	<p>The session underscored the urgent need for structured, systems-based approaches to tackle paediatric obesity and other noncommunicable diseases (NCDs), starting before birth and continuing through adolescence.</p> <p>Key recommendations included:</p> <ul style="list-style-type: none"> <li>• Integrating NCD prevention into existing maternal and child health programmes</li> <li>• Engaging youth in advocacy efforts and combating stigma</li> </ul>



		<ul style="list-style-type: none"><li>Investing in training frontline health workers to treat obesity and diabetes as medical conditions rather than lifestyle choices</li><li>Including community health workers (CHWs) and local education systems as essential parts of the care continuum.</li></ul> <p>Kenya was highlighted as a model example, demonstrating success through decentralised health reforms and effective community health worker engagement.</p>
--	--	--

## 4 Highlights from the strategic meetings in Geneva

During the WHA78, the FIP delegation conducted a series of high-level discussions with professional associations and WHO representatives to deepen collaboration, align strategic priorities, and identify concrete next steps.

Through these engagements FIP advanced its goal of positioning pharmacy as an essential partner in global health, secured consensus on priority areas for joint work, and established action points that will help inform FIP's programmes of work over the coming years. The key outcomes are summarised below.

WHO technical departments (Access to Medicines, Workforce, AMR, Patient Safety, SF Medicines, Assistive Technology, Education):

- Expressed mutual interest in refreshing the 2019 WHO-FIP Memorandum of Understanding to encompass workforce development, AMR, SF medicines and expanded pharmacy services, with a view to signing ahead of WHA79.
- Validated strong alignment between WHO's Access to Medicines Roadmap and FIP's upcoming strategic plan for 2025-2030.
- Agreed to collaborate on global pharmacy workforce intelligence and to use FIP's Development Goals and Brisbane Calls to Action as common reference points.



FIP meets with WHO at HQ in Geneva










WHO Academy:














- Confirmed shared commitment to competency-based education and agreed to scope joint-badged courses on AMR, vaccination leadership and digital health.
- Agreed to check the FIP Provision programme and FIP Seal against the Academy's emerging global badge scheme to ensure mutual recognition.
- Noted to identify pharmacy-specific modules and case studies that could enrich WHO learning modules in public health leadership, supply chains and workforce transformation.

## 5 Aligning WHA78 actions with FIP Development Goals and priority programmes













Several key actions (FIP statements) closely aligned with FIP's Development Goals (DGs) and priority programmes. These actions will be also emphasised in the FIP Strategic Plan 2025-2030. Table 6 demonstrates the mapping exercise towards FIP DGs and the rationale for each action.

Table 7. Mapping WHA78 actions and FIP Development Goals

WHA actions: Constituency and individual statement	DGs	Rationale	FIP priority programme
13.1 Follow-up to the political declaration of the third high-level meeting of the General Assembly on the prevention and control of non-communicable diseases	  	The statement reflects DG7 by urging the integration of pharmacists into national NCD strategies to support prevention, early detection, and treatment optimisation. It aligns with DG15 by promoting pharmacist-led services tailored to individuals and communities. It also supports DG18 by emphasising the pharmacist's role in improving access to essential medicines and health services for NCD management.	Non-communicable diseases programme (NCDs)
13.2 Mental health and social connection	  	The statement reflects DG7 by calling for the integration of pharmacists into national mental health strategies, supporting early identification, referral, and community-based care. It aligns with DG15 through its emphasis on pharmacists' roles in reducing stigma, addressing social determinants of health, and fostering connection. It also supports DG10 by advocating for the mental well-being of healthcare professionals, including pharmacists, through supportive and inclusive working environments.	Non-communicable diseases programme (NCDs); Self-care & management of common ailments programme
13.3 Universal health coverage: Primary health care	  	The statement reflects DG14 by emphasising that a pharmacy workforce is essential to deliver evidence-based, regulated primary health care, thereby safeguarding patient safety and quality use of medicines. It aligns with DG15 through its call for multidisciplinary teams that prioritise continuity of care and better patient outcomes, while also recognising the need to protect healthcare professionals from unsafe conditions and violence. It also contributes to DG18 by touching upon sustained investment in health professionals being the most cost-effective route to equitable, reliable access to essential medicines and services needed to achieve UHC.	Primary health care programme

13.5 Substandard and falsified medical products	 	The statement reflects DG19 by highlighting pharmacists' key role in protecting patients from SF medical products and promoting safe pharmaceutical care. It supports DG1 through the development and integration of new educational modules into pharmacy curricula to better prepare future pharmacists to address SF medicines.	Patient safety programme
13.7 Health and care workforce	  	The statement reflects DG1 by calling for pharmacy education to strengthen and sustain the global pharmacy workforce. It aligns with DG10 by addressing disparities in workforce distribution and the impact of migration on vulnerable health systems. It also supports DG13 through its call for integrating pharmacists into national workforce governance, ethical recruitment practices, and universal health coverage strategies.	Multinational needs assessment and surveillance programme
13.9 Global strategy for women's, children's and adolescents' health	  	The statement reflects DG10 by advocating for pharmacists' contributions to reducing health inequities for women, children, and adolescents. It aligns with DG13 through its call for integrating pharmacists into national health strategies for equity for women and children. It also supports DG18 by emphasising the pharmacist's role in ensuring the availability and responsible use of essential medicines and services.	Equity & equality programmes (including FIPWISE)
15. Antimicrobial resistance	  	The statement reflects DG17 by highlighting pharmacists' role in antimicrobial optimisation, public education, and stewardship leadership. It aligns with DG16 by advocating for pharmacists to be placed in leadership roles in AMS efforts. It also supports DG18 through its emphasis on multidisciplinary collaboration in monitoring, research, and advocacy to tackle AMR.	Antimicrobial stewardship programme
16.1 Strengthening the global architecture for health emergency prevention, preparedness, response and resilience	 	The statement reflects DG18 by urging priority access to medical products for frontline healthcare professionals and calling for resilient supply chains that guarantee continued delivery of essential medicines and services during crises. It aligns with DG21 through its emphasis on investing in education, training and working conditions, thereby building a pharmaceutical workforce and strengthening system resilience for future emergencies.	Humanitarian programme



16.2 Intergovernmental Negotiating Body to draft and negotiate a WHO convention, agreement or other international instrument on pandemic prevention, preparedness and response	 	The statement reflects DG16 through its focus on strengthening pharmacy's role in pandemic preparedness and infectious disease response. It aligns with DG18 by advocating for equitable access to essential health products during pandemics. It also supports DG21 by emphasising the need for resilient supply chains, coordinated global responses, and protecting pharmacy professionals on the front lines.	Humanitarian programme
18.3 Climate change and health	 	The statement aligns with DG13 by calling for a robust Global Action Plan with clear targets, timelines and indicators, and by urging the active involvement of healthcare professionals and civil society in designing, implementing and evaluating climate-health policies. It supports DG21 through its focus on cost-effective adaptation and mitigation measures, investment in resilient health services, and the role of pharmacists in promoting environmentally responsible practices that protect public health for future generations.	Sustainability in pharmacy programme
24.2 Review of and update on matters considered by the Executive Board were discussed during the 156th Executive Board	  	The statement reflects DG20 by urging Member States to integrate pharmacists into digital health strategies with appropriate support and infrastructure. It aligns with DG15 by highlighting the pharmacist's role in maternal and child health, dementia care, and preventive health. It also supports DG7 by advocating for sustained pharmacist-led innovations that extend access through integrated digital and community-based models.	Equity & equality programmes (including FIPWiSE); Non-communicable diseases programme (NCDs)
28.1 C. Integrated emergency, critical and operative care for universal health coverage and protection from health emergencies	  	The statement reflects DG21 by emphasising the role of pharmacists in strengthening health system resilience across all phases of emergency response. It aligns with DG7 through its call for formal integration of pharmacy into national emergency frameworks. It also supports DG18 by recognising pharmacists as critical to maintaining medicine supply and continuity of care in emergencies.	Disease prevention programme; Antimicrobial stewardship programme
28.1 L. WHO global plan of action to strengthen the role of the health system within a national multisectoral response to address interpersonal violence, in particular against women and girls, and against children	 	The statement reflects DG10 by calling for action to address violence against women and girls and to promote inclusive, safe work environments for pharmacy staff. It aligns with DG19 by recognising the impact of workplace violence on care quality and advocating for stronger safety measures. It also supports DG13 through its emphasis on developing structured, multidisciplinary responses and regulatory frameworks to address violence in healthcare settings.	Equity & equality programmes (including FIPWiSE)

## 6 FIP's success at the World Health Assembly: A reflection on the past three years

For the past three years, FIP has increased its presence and impact during the WHA week. One contributing factor that made this possible was the increased delegation to include FIP Bureau members and representatives from FIP Member Organisations since 2023. An increased number of delegates can therefore attend more side events and amplify the efforts of FIP during this important week on the global health calendar.

Table 8. Summary of FIP's three-year impact and successes at WHA

Variables	2022*	2023	2024	2025
Number of delegates	3	21	26	33
Number of individual statements delivered	3	5	5	10
Number of constituency statements delivered	2	3	3	3
Number of side events, receptions and networking engagements attended	18	28	42	66
Number of side events participated in (moderator and/or speaker)	1	4	11	8
Number of side events co-organised	0	0	2	2
Number of FIP-led side events	0	0	0	1
Number of strategic meetings	2	5	4	4

\*Before FIP full delegation, baseline

FIP's mission greatly benefits from the larger delegation at the WHA, which allows the Federation to attend more events, engage in networking, and increase the presence of pharmacy in Geneva. This is possible through the collaboration of the FIP Bureau and Member Organisations, who are willing to join forces with FIP to deliver this mission.




Figure 1. Comparison of FIP's impact and successes at WHA from 2022 to 2025

In May 2025, FIP strengthened the profession's visibility at the WHA78 by welcoming representatives from our member organisations to join the FIP delegation. This broader presence pursued six objectives:

1. Increase the profile and presence of pharmacy as integral to global health
2. Influence the global health agenda through policy statements (either as FIP or in collaboration with other stakeholders and partners, e.g., WHPA)
3. Ensure pharmacy is present at as many side events as possible
4. Support the side events of our partners, stakeholders and members
5. Host a side event, if possible and feasible
6. Network, collaborate, socialise.

Fourteen draft statements were prepared; after WHO consolidation, ten were delivered at the Assembly. These interventions addressed NCDs, mental health, women's and children's health, SF medical products, pharmaceutical workforce, AMR, pandemic preparedness, emergency care, UHC, and interpersonal violence.

Beyond the plenary, FIP delegates participated in—and where feasible co-hosted—multiple side-events, reinforcing pharmacy's contributions to primary health care, patient safety, and resilient health systems. Through these combined actions, FIP ensured that the voice of pharmacy was heard consistently across the WHA's deliberations and that the profession remains recognised as an essential partner in achieving global health goals.

## 7 Conclusions

FIP's participation at the World Health Assembly (WHA) continues to grow each year in both presence and impact.

This increasing engagement reflects the strong commitment not only from the FIP Bureau but also from our Member Organisations and individual members. Our advocacy message—"Pharmacists are part of the solution to global health challenges"—is gaining greater recognition year after year. The more that FIP delegates engage, the more visible and valued the contributions of pharmacists become on the global stage.

As we conclude our third year of a wider, coordinated, engaged FIP delegation to the WHA, we are proud of the impact we have made in shaping global health discussions. These achievements would not have been possible without the dedicated support of the FIP Bureau, our Member Organisations, and our wider network of committed professionals.

Looking ahead, we will continue to champion the role of pharmacists, pharmaceutical scientists and pharmacy educators across all aligned priorities and work collaboratively with other healthcare professionals, organisations, and stakeholders to advance healthcare for all, leaving no one behind. The insights and experiences gained over the past three years will continue to inform our priorities, ensuring that FIP's efforts remain aligned with the global health agenda and contribute meaningfully to policies that empower pharmacists worldwide.



International  
Pharmaceutical  
Federation

Fédération  
Internationale  
Pharmaceutique

Andries Bickerweg 5  
2517 JP The Hague  
The Netherlands

-

T +31 (0)70 302 19 70

F +31 (0)70 302 19 99

fip@fip.org

-

[www.fip.org](http://www.fip.org)

07/2025 | 78th WHA